Immune Globulin Intravenous (Human)
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Kiovig | — | 2006-01-19 | europa.eu ↗ |
Trials 228 · started per year
Also used as a comparator or background therapy in 77 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT02271165 Comparator | Nov 2014 → Mar 2017 | dermatomyositis | Thomas Jefferson University | Terminated | No outcome recorded |
| Phase 0 | NCT01841619 Comparator | Mar 2013 → Nov 2014 | cutaneous lupus erythematosus | University of California, Irvine | Completed | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT06753955 Background | Feb → Jul 2025 | anti-NMDA receptor encephalitis, autoimmune encephalitis | Arialys Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04634435 Background | Oct 2021 → Jan 2025 | plasma cell myeloma | Biohaven Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03010046 Background | Dec 2016 → Jun 2018 | — | Annexon, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT02659891 Comparator | May 2016 → Dec 2020 | polyomavirus infectious disease | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02586051 Background | Nov 2015 → Nov 2018 | end stage renal failure | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02042027 Comparator | Jul 2014 → Jul 2016 | corneal neovascularization, uveitis | University of Utah | Withdrawn | No outcome recorded |
| Phase 1 | NCT00271570 Comparator | Apr 2004 → Oct 2006 | Kawasaki disease | University of California, San Diego | Completed | No outcome recorded |
| Phase 217 trials | ||||||
| Phase 2 | NCT06686927 Background | Nov 2024 → Sep 2025 overdue | autoimmune thrombocytopenia | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 2 | NCT05634824 Comparator | Jan 2023 | autoimmune thrombocytopenia, pregnancy disorder | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05156710 Background | Jun 2022 → Oct 2025 overdue | transplant rejection | Sanofi | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04728425 Comparator | Aug 2020 → Jun 2023 | myasthenia gravis | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT03630211 Background | Jul 2018 → Aug 2026 overdue | diffuse scleroderma, interstitial lung disease, pulmonary hypertension | Paul Szabolcs | Recruiting | No outcome recorded |
| Phase 2 | NCT03194815 Comparator | Nov 2017 → Apr 2027 expected | autoimmune encephalitis, psychotic disorder | University of Cambridge | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02669277 Comparator | Aug 2015 → Feb 2016 | autoimmune thrombocytopenic purpura | Ain Shams University | Unknown | No outcome recorded |
| Phase 2 | NCT02201576 Comparator | Feb 2015 → Jul 2020 | chronic transplant rejection | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT02111161 Comparator | Apr 2014 → Sep 2016 | fournier gangrene, gas gangrene, necrotizing fasciitis, necrotizing soft tissue infection | Anders Perner | Completed | No outcome recorded |
| Phase 2 | NCT01895127 Comparator | Nov 2013 → Apr 2016 | transplant rejection | Brigham and Women's Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT01769027 Comparator | Jun → Dec 2013 | — | CNS Onlus | Withdrawn | No outcome recorded |
| Phase 2 | NCT01856205 Comparator | May → Aug 2009 | Japanese encephalitis | University of Liverpool | Completed | No outcome recorded |
| Phase 2 | NCT00809822 Comparator | Nov 2008 → Oct 2010 | bullous pemphigoid | Nihon Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT00230035 Comparator | Sep 2005 → ? | systemic lupus erythematosus | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase 2 | NCT00268788 Comparator | Aug 2005 → Feb 2008 | multifocal motor neuropathy | University of Aarhus | Completed | No outcome recorded |
| Phase 2 | NCT00176865 Comparator | Aug 2002 → Aug 2012 | Chediak-Higashi syndrome, Griscelli syndrome, Langerhans cell histiocytosis, X-linked lymphoproliferative syndrome | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT00002809 Background | Aug 1996 → Dec 2003 | leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease | Temple University | Completed | No outcome recorded |
| Phase 2/38 trials | ||||||
| Phase 2/3 | NCT07686770 Background | Aug 2026 → Sep 2027 expected | Kawasaki disease | Children's Hospital of Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05104762 Comparator | Sep 2021 → Mar 2022 | Guillain-Barre syndrome | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT03829566 Background | Nov 2019 → Jan 2025 | neuromyelitis optica | Northwestern University | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT03593902 Background | May 2018 → Oct 2019 | systemic sclerosis | Northwestern University | Terminated | No outcome recorded |
| Phase 2/3 | NCT02205762 Background | Nov 2016 → Jul 2026 overdue | Langerhans cell histiocytosis | North American Consortium for Histiocytosis | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT01522235 Comparator | Feb 2012 → May 2014 | autoimmune autonomic ganglionopathy | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 2/3 | NCT01412385 Background | Jun 2011 → May 2014 | immunodeficiency disease | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 2/3 | NCT01203345 Comparator | Jan 1988 → Mar 1991 | fetal growth restriction, infectious disease with sepsis | NICHD Neonatal Research Network | Completed | No outcome recorded |
| Phase 328 trials | ||||||
| Phase 3 | NCT07220915 Comparator | Jun 2026 → Dec 2029 expected | autoimmune disease, dysgammaglobulinemia, infectious disease, rheumatic disorder | Octapharma | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06920004 Comparator | Aug 2025 → Sep 2027 expected | polyneuropathy, inflammatory demyelinating, chronic | argenx | Recruiting | No outcome recorded |
| Phase 3 | NCT06867991 Comparator | Nov 2024 → Nov 2026 expected | anti-NMDA receptor encephalitis | The First People's Hospital of Changzhou | Recruiting | No outcome recorded |
| Phase 3 | NCT06290141 Comparator | Aug 2024 → Jul 2027 expected | polyneuropathy, inflammatory demyelinating, chronic | Sanofi | Recruiting | No outcome recorded |
| Phase 3 | NCT04656184 Comparator | Oct 2023 → Mar 2027 expected | Kawasaki disease | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT05494619 Background | Nov 2022 → Mar 2026 | Guillain-Barre syndrome | Hoffmann-La Roche | Withdrawn | No outcome recorded |
| Phase 3 | NCT06534450 Comparator | Sep 2022 → Nov 2023 overdue | — | Dobri Kiprov | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04968899 Comparator | Apr 2022 → Apr 2025 overdue | autoimmune thrombocytopenia | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT04935177 Background | Oct 2021 → Jun 2025 | — | Hansa Biopharma AB | Completed | No outcome recorded |
| Phase 3 | NCT04826588 Comparator | May 2021 → Nov 2022 | COVID-19–associated multisystem inflammatory syndrome in children | University Children's Hospital Basel | Completed | No outcome recorded |
| Phase 3 | NCT04535518 Background | Oct 2020 → Sep 2022 | Kawasaki disease | Children's Hospital of Fudan University | Withdrawn | No outcome recorded |
| Phase 3 | NCT04561115 Comparator | Sep 2020 → Mar 2022 | immunodeficiency disease | Grifols Therapeutics LLC | Completed | No outcome recorded |
| Phase 3 | NCT04302805 Comparator | Jul 2020 → Apr 2024 | — | Institute for Clinical and Experimental Medicine | Completed | No outcome recorded |
| Phase 3 | NCT04381936 Comparator | Mar 2020 → Sep 2028 expected | pneumonia | University of Oxford | Recruiting | No outcome recorded |
| Phase 3 | NCT04078568 Background | Jan 2020 → Dec 2024 | Kawasaki disease | Children's Hospital of Fudan University | Completed | No outcome recorded |
| Phase 3 | NCT03994783 Background | Jul 2019 → Jul 2021 | transplant rejection | Imperial College London | Terminated | No outcome recorded |
| Phase 3 | NCT03939637 Comparator | May 2019 → Apr 2024 | autoimmune thrombocytopenia | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 3 | NCT03742115 Comparator | Dec 2018 → Dec 2019 | hemophagocytic syndrome | Beijing Friendship Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03065244 Comparator | Feb 2017 → Aug 2020 | Kawasaki disease | University of California, San Diego | Completed | No outcome recorded |
| Phase 3 | NCT02697292 Comparator | Feb 2016 → Dec 2018 | autoimmune epilepsy | Mayo Clinic | Terminated | No outcome recorded |
| Phase 3 | NCT02269163 Comparator | Jan 2016 → Jan 2019 | immunodeficiency disease | Prometic Biotherapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02604810 Comparator | Jan 2016 → Sep 2017 | immunodeficiency disease | Grifols Therapeutics LLC | Completed | No outcome recorded |
| Phase 3 | NCT03200561 Comparator | Oct 2013 → Dec 2020 | Kawasaki disease | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01621204 Comparator | Oct 2012 → Jun 2019 | autoimmune thrombocytopenic purpura | McMaster University | Completed | No outcome recorded |
| Phase 3 | NCT01408550 Comparator | Aug 2011 → Sep 2013 | bullous pemphigoid | Nihon Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT00892112 Comparator | Nov 2009 → Jun 2018 | Parvoviridae infectious disease, cardiomyopathy | Prothya Biosolutions | Completed | No outcome recorded |
| Phase 3 | NCT00949065 Comparator | Aug 2009 → Jan 2011 | complex regional pain syndrome type 1 | University of Giessen | Withdrawn | No outcome recorded |
| Phase 3 | NCT00376077 Comparator | Aug 2005 → Mar 2016 | autoimmune thrombocytopenic purpura | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT05494593 Background | Feb 2023 → Aug 2025 | mucopolysaccharidosis type 2 | Takeda | Withdrawn | No outcome recorded |
| Phase 4 | NCT04589299 Comparator | Jun 2020 → Dec 2030 expected | polyneuropathy, inflammatory demyelinating, chronic | University of Aarhus | Recruiting | No outcome recorded |
| Phase 4 | NCT06223984 Comparator | Mar → Nov 2020 | — | Konya City Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01179893 Comparator | Mar 2007 → Jul 2010 | myasthenia gravis | University Health Network, Toronto | Completed | No outcome recorded |
| Phase not applicable10 trials | ||||||
| — | NCT05114941 Comparator | Jan → Dec 2026 expected | Guillain-Barre syndrome | The First Affiliated Hospital of Zhengzhou University | Not yet recruiting | No outcome recorded |
| — | NCT03647852 Comparator | Sep 2019 → Feb 2026 overdue | immunoglobulin A vasculitis | Children's Hospital of Fudan University | Recruiting | No outcome recorded |
| — | NCT03412188 Comparator | Aug 2018 → Sep 2021 | autoimmune thrombocytopenic purpura | Nayera Hazaa Elsherif | Completed | No outcome recorded |
| — | NCT02449746 Comparator | Aug 2015 → Aug 2017 | autoimmune disease, schizophrenia | University of Cambridge | Completed | No outcome recorded |
| — | NCT01547143 Background | Mar 2012 → May 2016 | secondary hemophagocytic lymphohistiocytosis | Asan Medical Center | Terminated | No outcome recorded |
| — | NCT01361178 Comparator | Jan 2011 → Jan 2016 | respiratory infections, recurrent, and failure to thrive with or without diarrhea | University of Pittsburgh | Completed | No outcome recorded |
| — | NCT01354587 Comparator | Oct 2010 → Aug 2012 | immunodeficiency disease | University of South Florida | Unknown | No outcome recorded |
| — | NCT01554930 Comparator | May → Nov 2010 | hand, foot and mouth disease | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| — | NCT01617317 Comparator | Jan 2010 → Nov 2011 | swine influenza | The University of Hong Kong | Completed | No outcome recorded |
| — | NCT00606905 Comparator | Nov 1999 → Mar 2009 | habitual spontaneous abortion, pregnancy loss, recurrent, 4 | University of Chicago | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06955793 Background | — | immunodeficiency disease | Takeda | Available | No outcome recorded |
Press releases naming this drug 64 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-15 | AstraZeneca | Ultomiris granted Priority Review in the US as treatment for adults with immunoglobulin A nephropathy astrazeneca.com ↗ |
| 2026-06-06 | AstraZeneca | Ultomiris demonstrated 43.4% reduction in proteinuria vs placebo in adults with immunoglobulin A nephropathy at 34 weeks in I CAN Phase III trial astrazeneca.com ↗ |
| 2026-05-04 | Takeda | Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID) takeda.com ↗ |
| 2026-04-21 | AstraZeneca | Ultomiris demonstrated statistically significant and clinically meaningful reduction of proteinuria in adults with immunoglobulin A nephropathy in I CAN Phase III trial astrazeneca.com ↗ |
| 2025-06-30 | Takeda | Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content 1 takeda.com ↗ |
| 2024-01-29 | Takeda | Takeda’s GAMMAGARD LIQUID ® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) takeda.com ↗ |
| 2024-01-03 | CSL Behring | CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe csl.com ↗ |
| 2023-09-25 | Takeda | Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia takeda.com ↗ |
| 2023-04-18 | CSL Behring | CSL Behring Receives FDA Approval for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 50mL Prefilled Syringe csl.com ↗ |
| 2021-08-09 | CSL Behring | The European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Task Force Has Strongly Recommended Subcutaneous Immunoglobulin (SCIg) for CIDP Maintenance Treatment csl.com ↗ |
| 2021-06-08 | CSL Behring | Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) To Be Covered Under Medicare Part B Effective July 18, Improving Access and Reducing Out-of-Pocket Costs for CIDP Patients csl.com ↗ |
| 2021-04-29 | CSL Behring | Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) Label Update Provides New Dosing Guidelines for Physicians, Allowing for Greater Flexibility in Treating CIDP Patients csl.com ↗ |
| 2021-02-12 | Pfizer | U.S. FDA Approves PANZYGA® for the Treatment of Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pfizer.com ↗ |
| 2020-12-09 | CSL Behring | HIZENTRA® (Immune Globulin Subcutaneous [Human] 20% Liquid) Receives Orphan-Drug Exclusivity for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) csl.com ↗ |
| 2020-04-21 | CSL Behring | CSL Behring Announces Results from Three Analyses of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) in Primary Immunodeficiency (PI) csl.com ↗ |
| 2020-02-11 | CSL Behring | PRIVIGEN® (Immune Globulin Intravenous (Human), 10% Liquid) Granted Orphan-Drug Designation for the Investigational Treatment of Systemic Sclerosis (SSc) csl.com ↗ |
| 2019-06-20 | CSL Behring | CSL Behring to showcase clinical advances and insights in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with Hizentra ® [human normal immunoglobulin, 20%, subcutaneous], at the 2019 Peripheral Nerve Society Annual Meeting csl.com ↗ |
| 2018-07-20 | CSL Behring | CSL Behring Hosts Symposium on Managing CIDP with Immunoglobulin, Supports 14 Scientific Posters and Two Oral Presentations at the 2018 Peripheral Nerve Society Annual Meeting csl.com ↗ |
| 2018-06-15 | CSL Behring | CSL Behring Presents New Data on Subcutaneous Immunoglobulin Treatment from the Largest CIDP Study, the PATH Trial, at the 4th Congress of the European Academy of Neurology csl.com ↗ |
| 2018-03-16 | CSL Behring | FDA Approves Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) csl.com ↗ |
| 2018-03-15 | CSL Behring | European Commission Approves Hizentra® [Human normal immunoglobulin (SCIg)] to Treat Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) csl.com ↗ |
| 2017-11-09 | CSL Behring | Lancet Neurology Publishes Results from CSL Behring Phase III Study of Hizentra® (Immune Globulin Subcutaneous [Human] 20% liquid) as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) csl.com ↗ |
| 2017-09-14 | CSL Behring | CSL Behring Announces FDA Approval of Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults csl.com ↗ |
| 2017-07-19 | CSL Behring | FDA Accepts CSL Behring’s Supplemental Biologics License Application for Hizentra® Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication csl.com ↗ |
| 2017-07-11 | CSL Behring | CSL Behring Awards Researchers to Advance Immunoglobulin Therapy in Treating Neurological Disorders csl.com ↗ |
| 2017-03-06 | Takeda | CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative to Patients’ Previous Immunoglobulin Therapy takeda.com ↗ |
| 2017-02-14 | CSL Behring | FDA Accepts CSL Behring’s Biologics License Application Supplement for Using Privigen® to Treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a Rare Neurological Condition csl.com ↗ |
| 2016-11-16 | Takeda | Shire launches CUVITRU™ [Immune Globulin Subcutaneous (Human), 20% Solution] in the U.S. for Primary Immunodeficiency takeda.com ↗ |
| 2016-11-12 | Takeda | Tolerability Data for Shire’s Cuvitru Accepted for Oral Presentation at the American College Of Allergy, Asthma & Immunology Annual Meeting takeda.com ↗ |
| 2016-09-14 | Takeda | Shire announces U.S. FDA approval of CUVITRU™ [immune globulin subcutaneous (human), 20% solution] treatment for Primary Immunodeficiency takeda.com ↗ |
| 2016-06-23 | CSL Behring | CSL Behring Announces Immunoglobulin Research Grant Winners csl.com ↗ |
| 2016-06-10 | Takeda | Shire announces completion of decentralized procedure in Europe for Immunoglobulin Treatment Cuvitru takeda.com ↗ |
| 2016-02-24 | CSL Behring | CSL Behring Adds Isoagglutinin Reduction Step to Privigen® Manufacturing Process csl.com ↗ |
| 2016-02-23 | CSL Behring | First Export of Privigen® From New Manufacturing Facility in Broadmeadows, Melbourne, Australia csl.com ↗ |
| 2015-02-02 | CSL Behring | FDA Approves New Dosing Option for CSL Behring’s Hizentra® csl.com ↗ |
| 2014-12-04 | CSL Behring | EMA Approves Amended Product Label for CSL Behring’s Hizentra® csl.com ↗ |
| 2014-10-30 | CSL Behring | Evidence presented at the 16th Biennial Meeting of the European Society for Immunodeficiencies (ESID) Supports Individualized Dosing with Hizentra® csl.com ↗ |
| 2014-05-20 | CSL Behring | CSL Behring Launches Hizentra® Co-Pay Relief Program csl.com ↗ |
| 2013-09-27 | CSL Behring | FDA Approves New Dosing Option for CSL Behring’s Hizentra® csl.com ↗ |
| 2013-09-27 | CSL Behring | CSL Behring Gains Approval to License Hizentra® in Japan for the Treatment of Primary Immunodeficiency and Secondary Immunodeficiency csl.com ↗ |
| 2013-09-03 | CSL Behring | CSL Behring Announces FDA Approval of a 10 g (50 mL) Vial Size for Hizentra® csl.com ↗ |
| 2013-04-04 | CSL Behring | European Commission Grants Marketing Authorization to CSL Behring’s Privigen® in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) csl.com ↗ |
| 2013-02-21 | CSL Behring | CSL Behring Announces New Vial Size of Privigen® for Treatment of Primary Immunodeficiency and Chronic Immune Thrombocytopenic Purpura csl.com ↗ |
| 2012-10-04 | CSL Behring | Study Supports Efficacy, Safety of Hizentra® in Japanese Patients with Primary Immunodeficiency Disease csl.com ↗ |
| 2012-10-04 | CSL Behring | New Model Compares Economic Value of Subcutaneous Immunoglobulin Therapy with Intravenous Immunoglobulin csl.com ↗ |
| 2012-07-06 | CSL Behring | CSL Behring Launches New Hizentra® Dosing Calculator App for Healthcare Professionals on the Move csl.com ↗ |
| 2012-06-27 | CSL Behring | PRIMA Study Shows Treatment with Privigen® Improved Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) csl.com ↗ |
| 2012-05-31 | CSL Behring | CSL Behring Submits Marketing Authorization Variation Application to European Medicines Agency (EMA) for Privigen® in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) csl.com ↗ |
| 2012-03-26 | CSL Behring | First patient enrolled in CSL Behring PATH trial to evaluate Immune Globulin Subcutaneous (Human) 20% Liquid, Hizentra®, in the treatment of CIDP csl.com ↗ |
| 2011-04-21 | CSL Behring | CSL Behring Receives European Commission Marketing Authorization for Hizentra, the first 20 Percent Subcutaneous Human Immunoglobulin for Treatment of Primary and Secondary Immunodeficiencies csl.com ↗ |
| 2011-04-19 | CSL Behring | FDA Approves Expansion of Innovative CSL Behring Hizentra® Production Facility in Bern, Switzerland csl.com ↗ |
| 2011-03-21 | CSL Behring | Study demonstrates relationship between subcutaneous IgG (SCIg) dosage and clinical outcomes with Hizentra treatment in patients with primary immunodeficiencies csl.com ↗ |
| 2011-03-19 | CSL Behring | New Model Provides Insights into Intravenous and Subcutaneous Immunoglobulin Pharmacokinetics in Patients with Primary Immunodeficiencies csl.com ↗ |
| 2011-02-24 | CSL Behring | CSL Behring Receives FDA Approval to Extend Shelf Life of Hizentra to 30 Months csl.com ↗ |
| 2010-10-07 | CSL Behring | Study Demonstrates Safety and Efficacy of Subcutaneous Vivaglobin as First-Line Therapy for Primary Immunodeficiency csl.com ↗ |
| 2010-10-07 | CSL Behring | Privigen Demonstrates Efficacy and Tolerability Among Patients With Various Immunodeficiencies, Data Show csl.com ↗ |
| 2010-10-07 | CSL Behring | Data Support Hizentra Efficacy, Safety After Dose-Equivalent Switch in Adult and Pediatric Patients with Primary Immunodeficiency csl.com ↗ |
| 2010-09-18 | CSL Behring | CSL Behring Receives FDA Approval to Extend Shelf Life of Hizentra from 18 Months to 24 Months csl.com ↗ |
| 2010-04-19 | CSL Behring | CSL Behring Receives FDA Approval to Extend Shelf Life for Privigen® from 24 to 36 Months csl.com ↗ |
| 2010-03-04 | CSL Behring | CSL Behring Receives FDA Approval of Hizentra™, First 20 Percent Subcutaneous Immunoglobulin Therapy csl.com ↗ |
| 2010-02-26 | CSL Behring | New Data Show IgPro20 Delivers Highest Available Subcutaneous Ig Concentration with Tolerability Comparable to Current Treatments csl.com ↗ |
| 2010-02-26 | CSL Behring | IgPro20, the First 20 Percent Subcutaneous Immunoglobulin, Demonstrates Efficacy Against Infections While Maintaining Tolerability in Patients with Primary Immunodeficiency csl.com ↗ |
| 2010-02-26 | CSL Behring | European Data Suggest Switching Patients to IgPro20 May Significantly Reduce Drug Administration Volume csl.com ↗ |
| 2009-05-01 | CSL Behring | CSL Behring Submits BLA Requesting Approval of Subcutaneous Human Immunoglobulin for Use as Replacement Therapy in Patients with Primary Immunodeficiencies csl.com ↗ |
Evidence & citations 80 cited values
Every value below carries the sentence it was read from. 316 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Immune Globulin Intravenous (Human) | “The investigators propose a double-blind controlled trial of 24 patients with Privigen® (Immune Globulin Intravenous (Human), 10% liquid treatment) with 3:1 randomization.” NCT01785056 ↗14“Active treatment will be intravenous immunoglobulin G (Gamunex, immune globulin intravenous \[human\], 10%), at a dose of 2 g/kg divided over five days (0.4 g/kg/day).” NCT00850005 ↗ “Immune Globulin Intravenous (Human), 10% (GAMMAGARD LIQUID/KIOVIG) Administered Intravenously or Subcutaneously” NCT00814320 ↗ |
| Known as | 10% = Immune Globulin Intraveneous (Human) | “10% = Immune Globulin Intraveneous (Human)” NCT00782106 ↗ |
| Known as | Bivigam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03164967 ↗ |
| Known as | CSL787 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04643587 ↗ |
| Known as | Cuvitru | “weekly 20% subcutaneous IG (SCIG; Cuvitru, Ig20Gly)” PMID 34036490 ↗ May 2021 |
| Known as | Flebogamma 5% DIF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02176863 ↗ |
| Known as | Gamimune N | “IVIG, either Gamimune N (Talecris Biotherapeutics, Inc., Clayton, NC) or Gamunex 10% (Talecris Biotherapeutics, Inc., Clayton, NC), both as a 10% solution” NCT00606905 ↗ |
| Known as | Gammagard | “A Placebo-controlled, Randomized, Double-Blind Phase II Clinical Study of Gammagard Intravenous Immunoglobulin (IVIg) for Treatment of Mild to Moderate Alzheimer's Disease” NCT00299988 ↗ |
| Known as | Gammagard [Immune Globulin Infusion (Human)] | “Gammagard [Immune Globulin Infusion (Human)]” NCT02123615 ↗ |
| Known as | GAMMAGARD LIQUID | “In the US the product is licensed (trade name GAMMAGARD LIQUID) for the intravenous (IV) and SC replacement therapy of antibody deficiency in patients with PID.” NCT01175213 ↗2“During this safety follow-up period, participants underwent treatment with the licensed product IGI, 10% (Gammagard Liquid).” NCT01485796 ↗ “Immune Globulin Intravenous (Human), 10% (GAMMAGARD LIQUID/KIOVIG)” NCT00814320 ↗ |
| Known as | GAMMAGARD LIQUID, 10% | “Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease.” PMID 21424824 ↗ Mar 2011 |
| Known as | GAMMAGARD LIQUID/KIOVIG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02549170 ↗ |
| Known as | gammaglobulin | “To test the efficacy of intravenous gamma globulin (IVGG) in preventing coronary artery aneurysms in children with Kawasaki Syndrome.” NCT00000520 ↗ |
| Known as | GAMMAPLEX | “The main objective of this study is to see if GAMMAPLEX is efficacious with respect to Food and Drug Administration (FDA) minimal requirements (no more than 1 serious, acute,...” NCT00278954 ↗6“Gammargard, Gammaplex, Gamunex, or Octogam IGIV Product” NCT02269163 ↗ |
| Known as | Gammaplex 5% IGIV | “Gammaplex 5% IGIV administered intravenously” NCT02199925 ↗ |
| Known as | GAMUNEX | “Active treatment will be intravenous immunoglobulin G (Gamunex, immune globulin intravenous \[human\], 10%), at a dose of 2 g/kg divided over five days (0.4 g/kg/day).” NCT00850005 ↗7“Placebo followed by IVIG 1 g/kg (Gamunex® Immune Globulin Intravenous \[Human\], 10%; Bayer)\* x 1 dose” NCT00376077 ↗ “both given over 1 hour, followed in both cases by IVIG (Gamunex 10%) 1 g/kg over 2-3 hours” PMID 32282882 ↗ Apr 2020 “GAMUNEX® (immune globulin intravenous (human) 10% caprylate/chromatography purified).” NCT00845650 ↗ “Gammargard, Gammaplex, Gamunex, or Octogam IGIV Product” NCT02269163 ↗ |
| Known as | Gamunex 10% | “IVIG, either Gamimune N (Talecris Biotherapeutics, Inc., Clayton, NC) or Gamunex 10% (Talecris Biotherapeutics, Inc., Clayton, NC), both as a 10% solution” NCT00606905 ↗ |
| Known as | Gamunex-C | “Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease.” PMID 27342758 ↗ Jun 201610“Gamunex-C \[immune globulin injection (human) 10% caprylate/chromatography purified\] is a sterile solution of human immune globulin protein.” NCT03401073 ↗ “Gamunex®-C Plus Standard Medical Treatment to Prevent Infections” NCT07582432 ↗ |
| Known as | Hizentra | “A Pilot Study to Assess Tolerability of Subcutaneous Immunoglobulin Treatment (Hizentra) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation” NCT03401268 ↗8“Immunoglobulin (HIZENTRA) subcutaneously 0.54 g/kg/week for 26 weeks.” NCT04589299 ↗ “IgPro20 (Subcutaneous Immunoglobulin, Hizentra®)” NCT04137224 ↗ “Drug: Immunoglobulin (Hizentra)” NCT02271165 ↗ |
| Known as | human gamma globulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02822027 ↗ |
| Known as | human immunoglobulin | “Treatment of Hypersensitivity Syndrome (DRESS) With Tegeline® (Human Immunoglobulin)” NCT00505648 ↗1“human immunoglobulin infusion (IVIg)” NCT00004833 ↗ |
| Known as | human immunoglobulin G | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04044690 ↗ |
| Known as | Human normal Immunoglobulin | “Human normal immunoglobulin 200 mg/mL (including immunoglobulin G (IgG) no less than 95 %) administered subcutaneously.” NCT07346859 ↗6“Participants received Octagam 10% (human normal immunoglobulin) 1 g/kg intravenously once a day for 2 days.” NCT00426270 ↗ “Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)” NCT01951924 ↗ “(Intravenous) Human Normal Immunoglobulin (IVIg) 10%” NCT07059000 ↗ “Intravenous human normal immunoglobulin (IVIg) 10%” NCT07552987 ↗ “Gammaplex® (Human Normal Immunoglobulin)” NCT02246855 ↗ |
| Known as | human normal immunoglobulin 10% | “The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as the minimum trough level of serum...” NCT01313507 ↗ |
| Known as | Human normal immunoglobulin G (IgG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02774239 ↗ |
| Known as | Ig20Gly | “weekly 20% subcutaneous IG (SCIG; Cuvitru, Ig20Gly)” PMID 34036490 ↗ May 2021 |
| Known as | IGI, 10% | “IGSC, 10% is abbreviated to IGI, 10% \[IMMUNE GLOBULIN INFUSION (HUMAN), 10%\]” NCT01175213 ↗ |
| Known as | IGIV | “Immune Globulin Intravenous (IGIV)” NCT04346108 ↗ |
| Known as | IGIV, 10% | “The purpose of this study is to evaluate the tolerability of IGIV, 10% given subcutaneously and the pharmacokinetics of immunoglobulin G (IgG) following subcutaneous (SC)...” NCT00546871 ↗4“The purpose of this study is to assess the safety and efficacy of Immune Globulin Intravenous (Human), 10% (IGIV 10%) in subjects with primary immunodeficiency disorders.” NCT00157079 ↗ “IGSC, 10% is the same product as IMMUNE GLOBULIN INTRAVENOUS (HUMAN), 10% (IGIV, 10%)” NCT01175213 ↗ “Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg” NCT00818662 ↗ “Immune Globulin Intravenous (Human), 10% (IGIV, 10%)” NCT01736579 ↗ |
| Known as | IGIV-C | “Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve...” NCT00090194 ↗6“subcutaneously (SC) administered 10 % caprylate/chromatography purified human immune globulin injection (IGIV-C, GAMUNEX®) compared with intravenously (IV) administered IGIV-C.” PMID 27342758 ↗ Jun 2016 |
| Known as | IGIV-C 10% | “Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve...” NCT00090194 ↗2“We therefore set out to test two different doses of a new formulation of immunoglobulin termed IGIV-C 10% for suppression of both clinical and MRI disease activity as well as safety.” PMID 18645164 ↗ Jul 2008 “Gamunex-C (IGIV-C 10%)” NCT07540221 ↗ |
| Known as | IgPro10 | “A Multicenter Study on the Efficacy, Safety and Pharmacokinetics of IgPro10 in Patients With Primary Immunodeficiency (PID)” NCT00168025 ↗6“Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)” NCT00322556 ↗ |
| Known as | IgPro20 | “Human Normal Immunoglobulin for Subcutaneous Administration (IgPro20) is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at...” NCT00419341 ↗13“evaluated the efficacy, tolerability, and safety of IgPro20 (Hizentra®; L-proline-stabilized 20 % human SCIG) in adult and pediatric Japanese patients with PID.” PMID 24504846 ↗ Feb 2014 “IgPro20 is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals.” NCT00542997 ↗ “IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human immunoglobulin for subcutaneous (SC) use.” NCT01458171 ↗ “IgPro20 is a solution for infusion for subcutaneous administration.” NCT07076446 ↗ |
| Known as | IGSC | “Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%)” NCT04346108 ↗ |
| Known as | IGSC 20% | “Approximately 60 subjects will be enrolled in order to have approximately 20 adult subjects and 20 pediatric subjects treated with subcutaneously administered Immune Globulin...” NCT02806986 ↗ |
| Known as | Immune Globulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05952804 ↗ |
| Known as | Immune Globulin (Human) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03351933 ↗ |
| Known as | Immune Globulin (Human), 10% Caprylate/Chromatography Purified | “This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified...” NCT02473965 ↗1“A Multicenter, Prospective, Open-label, Non-controlled Clinical Trial to Assess the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified...” NCT02413580 ↗ |
| Known as | Immune Globulin Infusion (Human) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01485796 ↗ |
| Known as | IMMUNE GLOBULIN INFUSION (HUMAN), 10% | “IGSC, 10% is abbreviated to IGI, 10% \[IMMUNE GLOBULIN INFUSION (HUMAN), 10%\]” NCT01175213 ↗ |
| Known as | immune globulin injection (human) | “This prospective, Phase III study assessed the pharmacokinetics (PK), safety and tolerability of immune globulin subcutaneous, human - klhw 20% solution (IGSC-C 20%) in...” PMID 31621458 ↗ Oct 2019 |
| Known as | Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified | “IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified” NCT02473952 ↗ |
| Known as | Immune Globulin Intravenous | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07202065 ↗ |
| Known as | Immune Globulin Intravenous (Human), 10% | “Immune Globulin Intravenous (Human), 10%, IGIV-C, 10%” NCT00606905 ↗ |
| Known as | Immune Globulin Intravenous (Human), 10% (IGIV, 10%) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01736579 ↗ |
| Known as | Immune Globulin Intravenous (Human), 10%, IGIV-C, 10% | “Immune Globulin Intravenous (Human), 10%, IGIV-C, 10%” NCT00606905 ↗ |
| Known as | Immune globulin subcutaneous (Human) | “Approximately 60 subjects will be enrolled in order to have approximately 20 adult subjects and 20 pediatric subjects treated with subcutaneously administered Immune Globulin...” NCT02806986 ↗ |
| Known as | immunoglobulin | “intravenous immunoglobulin (given intravenously at a dose of 5g per month for 6 months)” NCT02834468 ↗ |
| Known as | Immunoglobulin Intravenous (Human) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00168038 ↗ |
| Known as | Immunoglobulin Intravenous (Human) 10% | “High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)” NCT01313507 ↗ |
| Known as | Immunoglobulin subcutaneous (human) 20% liquid, Hizentra | “Immunoglobulin subcutaneous (human) 20% liquid, Hizentra” NCT02271165 ↗ |
| Known as | ImmunoRel | “Children received either saline or intravenous immunoglobulin (IVIG) \[ImmunoRel™ (batch 20081217)\] at a dose of 400mg/kg/day for 5 days” NCT01856205 ↗ |
| Known as | intravenous immune globulin | “intravenous immune globulin (IVIG)” NCT05520892 ↗ |
| Known as | Intravenous Immunoglobulin | “Mini-pool intravenous immunoglobulin (IVIG) is a plasma-derived biologic prepared from small pools of locally donated human plasma using a validated, virus-inactivated,...” NCT07068126 ↗63“The purpose of this research is to study the effects of Privigen (intravenous immunoglobulin) on the skin in patients with scleroderma.” NCT01785056 ↗ “Determine the effect of intravenous immunoglobulin on recovery time of patients with proximal diabetic neuropathy.” NCT00004407 ↗ “Intravenous immunoglobulin (IVIG): 0.5 gm/kg/day i.v. on days 16-19” NCT03286556 ↗ “Intravenous immunoglobulin (IVIG) and oral prednisolone.” NCT02695797 ↗ “Drug: Gamunex Intravenous Immunoglobulin” NCT01281969 ↗ “Intravenous Immunoglobulin” NCT07231523 ↗ “Intravenous Immunoglobulin” NCT02586051 ↗ |
| Known as | Intravenous immunoglobulin (IVIG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00176865 ↗ |
| Known as | Intravenous Immunoglobulin G | “Intravenous Immunoglobulin G (IVIG) therapy has been widely used for a variety of indications in newborn period such as alloimmune neonatal thrombocytopenia and an adjunctive...” NCT03130517 ↗1“Active treatment will be intravenous immunoglobulin G (Gamunex, immune globulin intravenous \[human\], 10%), at a dose of 2 g/kg divided over five days (0.4 g/kg/day).” NCT00850005 ↗ |
| Known as | intravenous immunoglobulin therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04548557 ↗ |
| Known as | Intravenous immunoglobulins | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04968899 ↗ |
| Known as | IVGG | “To test the efficacy of intravenous gamma globulin (IVGG) in preventing coronary artery aneurysms in children with Kawasaki Syndrome.” NCT00000520 ↗ |
| Known as | IVIG | “This study is a prospective, multi-center, randomized controlled study to evaluate the efficacy and safety of efgartigimod (EFG) and intravenous immunoglobulin (IVIG) in the...” NCT07231523 ↗95“In this open-label pilot study, we propose to provide free sialic acid to muscle cells of HIBM patients by intravenous infusions of immune globulin (IvIg), a glycoprotein that...” NCT00195637 ↗ “Intravenous Immunoglobulin G (IVIG) therapy has been widely used for a variety of indications in newborn period such as alloimmune neonatal thrombocytopenia and an adjunctive...” NCT03130517 ↗ “Intravenous Immunoglobulin IVIg is a medication that has been used to treat diseases like Kawasaki disease, systemic juvenile rheumatoid arthritis, lupus nephritis, and...” NCT00001768 ↗ “intravenous immunoglobulin:0.2g-0.4g/kg/d,ivgtt, 3-5 days.If disease progression occurs after completion of treatment, the dose of salvage therapy (IVIG 0.4g/kg/d) was...” NCT05604859 ↗ “This study is a double-blind, placebo-controlled, randomized clinical trial to determine whether IVIG is effective in improving motor scores in patients with myasthenia gravis...” NCT00306033 ↗ “We hypothesise, that the use of intravenous immunoglobulins ( IVIG) will decrease the number of circulating antibodies thereby decreasing symptom severity and shortening the...” NCT00615797 ↗ “Mini-pool intravenous immunoglobulin (IVIG) is a plasma-derived biologic prepared from small pools of locally donated human plasma using a validated, virus-inactivated,...” NCT07068126 ↗ “IVIG is a fractionated blood product whose off-label use for treating a variety of conditions, including spontaneous recurrent miscarriage, has continued to grow in recent years.” PMID 17166218 ↗ Dec 2006 “The purpose of this study is to determine whether Intravenous Immunoglobulin (IVIG) is safe and effective in the acute treatment of pain crises in sickle cell disease.” NCT01757418 ↗ “This study will examine whether high-dose intravenous immunoglobulin (IVIG) is safe and effective for treating cerebellar ataxia-degeneration of the cerebellum” NCT00034242 ↗ “Previous uncontrolled studies suggested a possible benefit of intravenous immunoglobulin (IVIg) in parvovirus B19 (B19V)-related dilated cardiomyopathy (DCM).” PMID 33347677 ↗ Jan 2021 “OBJECTIVE: We tested biweekly infusions of IV immunoglobulin (IVIg) as a possible treatment for mild to moderate Alzheimer disease (AD) dementia.” PMID 28381506 ↗ Apr 2017 “Human normal immunoglobulin (IVIg) 2g/kg intravenously as a single dose in line with guidance for dosing and administration in Kawasaki disease” NCT04826588 ↗ “This study explores the effects of an immune-modulating blood-derived product, intravenous immunoglobulin (IVIG), in treating neuropathic pain.” NCT00850005 ↗ “intravenous immunoglobulin (IVIG) can prevent bacterial infections in lung transplant patients with low serum levels of immunoglobulin.” NCT00115778 ↗ “Intravenous immunoglobulin (IVIG) is often used as second-line treatment in steroid-unresponsive central nervous system demyelination” NCT02398994 ↗ “Additionally, intravenous immunoglobulin (IVIg) background therapy will be administered once a day (QD) for 5 days.” NCT05494619 ↗ “group 2: 27 patients undergo intravenous injection of immunoglobulin for 5 consecutive days of IVIG 0.4gm/kg/day.” NCT05104762 ↗ “Intravenous Immunoglobulin (IVIg) is a medication obtained from the pooled plasma of healthy human blood donors” NCT00299988 ↗ “treating the pregnant mother with intravenous immune globulin (IVIG) will prevent the development of CHB” NCT00460928 ↗ “When initiating Parkland, treatment group (Group A) will receive intravenous immunoglobulin IVIG” NCT05134792 ↗ “Intravenous immunoglobulin (IVIG) 0.8 g/kg will be given within 12 hours after randomization.” NCT02690038 ↗ “Patients receive Intravenous Immunoglobulin (IVIG) at a total dose of 2 g/kg body weight.” NCT07532707 ↗ “IVIG, 400mg/kg/d, intravenous administration, continuous administration for 3-5 days.” NCT06686927 ↗ “IVIg: IVIG 1 g/kg x1 (no steroids for pre-medication or adjunctive therapy)” NCT03939637 ↗ “Patients would be treated with IVIg 400mg/kg per day for 5 days monthly.” NCT05634824 ↗ “Intravenous Immunoglobulin (IVIG) in combination with standard care” NCT04261426 ↗ “Intravenous immunoglobulin (IVIG): 0.5 gm/kg/day i.v. on days 16-19” NCT03286556 ↗ “intravenous immunoglobulin (IVIg) could help to reduce symptoms.” PMID 38353301 ↗ Feb 2024 “IVIg would be given in combination with Rituximab intravenously.” NCT04400994 ↗ “Intravenous immunoglobulin (IVIG), 10% solution for infusion” NCT05422365 ↗ “Intravenous immunoglobulin (IVIG), 10% solution for infusion” NCT07193953 ↗ “Intravenous immunoglobulin (IVIG) and oral prednisolone.” NCT02695797 ↗ “Intravenous Immunoglobulin (IVIG) (Gamunex-C) Group” NCT02697292 ↗ “intravenous human immune globulin (IVIG) or placebo” NCT00004286 ↗ “intravenous immunoglobulin (IVIG) induction therapy” PMID 17175311 ↗ Dec 2006 “using high-dose intravenous immunoglobulin (IVIg)” NCT00001287 ↗ “high-dose intravenous immune globulin (IVIG)” NCT00004744 ↗ “human intravenous immunoglobulin (IVIg)” NCT02343211 ↗ “10% intravenous immunoglobulin (IVIG)” NCT04728425 ↗ “10% intravenous immunoglobulin (IVIg)” NCT02372149 ↗ “human immunoglobulin infusion (IVIg)” NCT00004833 ↗ “intravenous immune globulin (IVIG)” NCT00004772 ↗ “intravenous immune globulin (IVIG)” NCT05520892 ↗ “Intravenous immunoglobulin (IVIG)” NCT07202052 ↗ “Intravenous immunoglobulin (IVIG)” NCT06753955 ↗ “Intravenous immunoglobulin (IVIG)” NCT00271570 ↗ “Intravenous immunoglobulin (IVIg)” NCT04381936 ↗ “Intravenous immunoglobulin (IVIg)” NCT05156710 ↗ “Intravenous immunoglobulin (IVIg)” NCT03866577 ↗ “One dose of IVIG” NCT04474223 ↗ “Octagam (IVIG)” NCT00430885 ↗ “IVIG” NCT02449746 ↗ |
| Known as | IVIg-C | “Immune globulin 10% caprylate/chromatography purified (IVIg-C)” PMID 35350948 ↗ Apr 2022 |
| Known as | IVIG-SN | “The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of Immune Globulin Intravenous (Human) IVIG-SN™ in subjects with primary immunodeficiency diseases.” NCT01406470 ↗ |
| Known as | KIOVIG | “Gammagard and Kiovig are the brand names for the same immunoglobulin compound.” NCT02549170 ↗4“Immune Globulin Intravenous (Human), 10% (GAMMAGARD LIQUID/KIOVIG)” NCT00814320 ↗ “In the EU this product is licensed (trade name KIOVIG)” NCT01175213 ↗ |
| Known as | Nanogam | “Sanquin developed a 100 mg/ml IVIg product (Nanogam 100 mg/ml).” NCT01985373 ↗ |
| Known as | NewGam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02638207 ↗ |
| Known as | Newnorm | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04640142 ↗ |
| Known as | NPB-01 | “Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive days.” NCT01696500 ↗ |
| Known as | Octagam | “Intravenous immunoglobulins (IVIG) infusions ("Octagam"; dosing: initially on three consecutive days 0,4 g/kg KG, thereafter 0,4 g/kg KG every month, after 12 months of...” NCT00545493 ↗ |
| Known as | Octagam 10% | “Participants received Octagam 10% (human normal immunoglobulin) 1 g/kg intravenously once a day for 2 days.” NCT00426270 ↗ |
| Known as | Panzyga | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03866798 ↗ |
| Known as | Privigen | “10% Immunoglobulin G (IgG) liquid formulation of human normal immunoglobulin (Privigen®) administered intravenously during Restabilization Period of the study and/or as Rescue...” NCT01545076 ↗13“Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the...” PMID 23781960 ↗ Jun 2013 “Single administration of intravenous immunoglobulin solution Privigen® (CSL Behring AG, Bern, Switzerland) at a dose of 2g / kg.” NCT02899702 ↗ “Immunoglobulin (PRIVIGEN) intravenously 2 g/kg/4week for 26 weeks.” NCT04589299 ↗ “Privigen® IVIg comes in vials containing 10% active ingredient.” NCT07193953 ↗ “IgPro10 (Intravenous Immunoglobulin, Privigen®)” NCT04137224 ↗ “Privigen” NCT00168038 ↗ |
| Known as | QIVIGY | “The purpose of this study is to evaluate the efficacy and safety of QIVIGY (Intravenous Human Normal Immune Globulin 10%) compared with placebo in adult participants with stiff...” NCT07552987 ↗1“A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)” NCT06752356 ↗ |
| Known as | TAK-881 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05755035 ↗ |
| Known as | Tegeline | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00505648 ↗ |
| Known as | therapeutic immune globulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00806767 ↗ |
| Known as | Venoglobulin-IH | “High-dose intravenous immunoglobulin (Venoglobulin-IH)” NCT00348296 ↗ |
| Known as | Vivaglobin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00520494 ↗ |
| Action | Inhibit | “Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies” NCT00090194 ↗ |
| Modality | Protein / enzyme biologic | “intravenous gamma globulin” NCT00000520 ↗ |
| Route | Intravenous | “400 mg/kg/day of intravenous gamma globulin for four consecutive days plus aspirin as above.” NCT00000520 ↗ |